# GSK Plc seeks EMA approval for RSV vaccine in adults 18+

- Link: https://www.directorstalkinterviews.com/gsk-plc-seeks-ema-approval-for-rsv-vaccine-in-adults-18/4121202000
- Published: 2025-06-13T07:37:34+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that the European Medicines Agency (EMA) has accepted
the company’s regulatory application to expand the use of its adjuvanted recombinant
respiratory syncytial virus (RSV) vaccine to include adults from 18 years of age.
_Arexvy_ was the first RSV vaccine approved in the European Economic Area for the
prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged
60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.

RSV is a common contagious virus affecting the lungs and breathing passages and 
impacts an estimated 64 million people of all ages globally every year.^(1) RSV 
can exacerbate certain medical conditions, and lead to severe illness resulting 
in hospitalisation and even death.^(2 3 4)

A European regulatory decision on this submission is anticipated in H1 2026. GSK
is continuing to seek expanded indications for its RSV vaccine in other geographies
including the US and Japan.

**References:**

1.     National Institute of Allergy and Infectious Diseases, Respiratory Syncytial
Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-
syncytial-virus-rsv. Accessed June 2025

2.     Osei-Yeboah R, et al. Estimation of the Number of Respiratory Syncytial Virus-
Associated Hospitalizations in Adults in the European Union. _J Infect Dis_ 2023
May 29;228(11):1539-1548. doi: 10.1093/infdis/jiad189

3.     Atamna A, Babich T, Froimovici D, Yahav D, Sorek N, Ben-Zvi H, Leibovici 
L, Bishara J, Avni T. Morbidity and mortality of respiratory syncytial virus infection
in hospitalized adults: Comparison with seasonal influenza. Int J Infect Dis. 2021
Feb;103:489-493. doi: 10.1016/j.ijid.2020.11.185.

4.     Falsey, AR _et al_. Respiratory syncytial virus infection in elderly and 
high-risk adults, in _New Engl J Med_ 2005; 352:1749-59. doi: 10.1056/NEJMoa043951

Share on:
